IDEAYA Biosciences, Inc.

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Headquartered in South San Francisco, California, the company aims to advance first-in-class and/or best-in-class therapeutics with a primary focus on synthetic lethality, an emerging class of precision medicine targets.

Products & Services

Darovasertib (IDE196):A therapeutic in the pipeline, likely targeting specific cancer indications (details under clinical trials).

MAT2A (IDE397):A potential first-in-class MAT2A inhibitor being tested in clinical trials for MTAP-deletion urothelial cancer.

DLL3 ADC (IDE849):A therapeutic candidate in the pipeline for cancer treatment.

PARG (IDE161):A therapeutic under development, with ongoing clinical trials.

Pol Theta (IDE705):A pipeline candidate targeting cancer through specific mechanisms.

Specialties

Precision Medicine Synthetic Lethality Target and Biomarker Discovery Small Molecule Therapeutics Protein Degrader Therapeutics Clinical Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 345000000 MR: - FA: $345.0 million FAN: 345000000	D: 2026-06-10 FD: 2026-06-10	6 investors
2	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2026-06-08 FD: 2026-06-08	-
3	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2026-06-08 FD: 2026-06-08	6 investors
4	RT: Public Offering T: - FT: Public Offering	A: 302400000 MR: - FA: approximately $302.4 million FAN: 302400000	D: 2024-07-11 FD: 2024-07-11	4 investors
5	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: $200.0 million FAN: 200000000	D: 2024-07-09 FD: 2024-07-09	4 investors
6	RT: Public Offering T: - FT: Public Offering	A: 263000000 MR: - FA: approximately $263,000,000 FAN: 263000000	D: 2024-07-09 FD: 2024-07-09	4 investors
7	RT: Public Offering T: - FT: Public Offering	A: 201000000 MR: - FA: approximately $201 million FAN: 201000000	D: 2023-04-27 FD: 2023-04-27	5 investors
8	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: $175,000,000 FAN: 175000000	D: 2023-04-24 FD: 2023-04-24	5 investors
9	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: up to $150 million FAN: 150000000	D: 2023-04-24 FD: 2023-04-24	3 investors

Public Offering Latest

2026-06-10

$345.0M

6 investors (Pro only)

Public Offering 2026-06-08

$300.0M

Underwritten Public Offering 2026-06-08

$300.0M

View 8 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Y

Yujiro S. Hata

President and Chief Executive Officer, Founder

LinkedIn (Pro only)

D

Darrin M. Beaupre

Chief Medical Officer

M

Michael White

Chief Scientific Officer

LinkedIn (Pro only)

J

Joshua Bleharski

Chief Financial Officer

S

Stu Dorman

Chief Commercial Officer

D

Daniel A. Simon

Chief Business Officer

View 26 more team members with Pro

Unlock Full Team Directory

Recent News